More patients enrolled faster with fewer sites

A global biopharmaceutical company conducted a Phase 3 study for an RSV vaccine across the US and Germany. The study involved 121 sites overall, including 11 Accellacare sites. The goal was to evaluate vaccine efficacy and safety in a large adult population.

Recruiting and retaining a large number of participants across multiple geographies posed logistical and operational challenges. Many sites struggled with slower enrolment rates and lower retention, which threatened study timelines and data integrity.

Accellacare implemented a high-efficiency site strategy, leveraging centralised recruitment tools and site-level engagement best practices. Sites proactively reviewed electronic health records and collaborated with local healthcare providers to identify eligible participants early. Enhanced patient engagement and retention protocols were also deployed to ensure participants remained in the study through completion.

Accellacare sites demonstrated markedly superior performance compared to non-Accellacare sites across key patient recruitment and retention metrics. Accellacare sites enrolled 40% more patients per site 40% faster than their non Accellacare counterparts. Despite representing only 9% of the total sites, Accellacare contributed 13% of total randomisations. Notably, seven of the top 20 recruiting sites, globally, were Accellacare locations. 

A total of 2,627 randomisations were achieved at just 11 Accellacare sites for a rate of 239 randomisations per site, in contrast to 170 randomisations per non-Accellacare site. Monthly performance was also stronger, with 34 randomisations per site per month versus 24 at non-Accellacare sites. 

The retention rate at Accellacare sites was an impressive 98.5%, compared to 85.1% retention observed at non-Accellacare locations.

By enrolling more patients with fewer sites, Accellacare helped accelerate study timelines, reduce operational costs, and improve data quality. Their performance demonstrated the value of strategic site selection and proactive patient engagement in large-scale vaccine trials.